An updated natural history model of cervical cancer: derivation of model parameters.
暂无分享,去创建一个
Allan Hildesheim | Stephen Sy | Rolando Herrero | Ana Cecilia Rodriguez | Mark Schiffman | A. Hildesheim | A. Rodriguez | M. Schiffman | R. Herrero | Jane J. Kim | Jane J Kim | Emily A Burger | Nicole G Campos | E. Burger | Nicole G. Campos | S. Sy | Monisha Sharma | Monisha Sharma | N. Campos
[1] K. Auranen,et al. Impact of Vaccination on 14 High-Risk HPV Type Infections: A Mathematical Modelling Approach , 2013, PloS one.
[2] J. Cuzick,et al. A population‐based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination , 2013, International journal of cancer.
[3] E. Kliewer,et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. , 2012, Journal of the National Cancer Institute.
[4] Nicolas Wentzensen,et al. Molecular mapping of high‐grade cervical intraepithelial neoplasia shows etiological dominance of HPV16 , 2012, International journal of cancer.
[5] Natasha K. Stout,et al. Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines , 2012, PharmacoEconomics.
[6] E. Unger,et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. , 2011, The Journal of infectious diseases.
[7] E. Unger,et al. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States--National Health And Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact? , 2011, The Journal of infectious diseases.
[8] S. Kulasingam,et al. Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force , 2011 .
[9] M. Schiffman. The Need for Forward-Looking Decision Analyses to Guide Cervical Cancer Prevention , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[10] C. Wheeler,et al. Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[11] T. Iftner,et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. , 2010, Journal of the National Cancer Institute.
[12] Diane Solomon,et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. , 2010, Journal of the National Cancer Institute.
[13] P. Castle,et al. Benefits and risks of HPV testing in cervical cancer screening. , 2010, The Lancet. Oncology.
[14] J. Savarino,et al. Bayesian Calibration of Microsimulation Models , 2009, Journal of the American Statistical Association.
[15] S. Goldie,et al. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States , 2009, BMJ : British Medical Journal.
[16] Elamin H Elbasha,et al. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model , 2009, BMC infectious diseases.
[17] C. Wheeler,et al. Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States , 2009, Journal of the National Cancer Institute.
[18] Diane Solomon,et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. , 2008, Vaccine.
[19] Sue J Goldie,et al. Health and economic implications of HPV vaccination in the United States. , 2008, The New England journal of medicine.
[20] Charlotte Paul,et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. , 2008, The Lancet. Oncology.
[21] M. Plummer,et al. A 2-Year Prospective Study of Human Papillomavirus Persistence Among Women With a Cytological Diagnosis of Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesion , 2008 .
[22] Jeremy D Goldhaber-Fiebert,et al. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination , 2007, Population health metrics.
[23] Jose Jeronimo,et al. Human papillomavirus and cervical cancer , 2007, The Lancet.
[24] Jeremy D Goldhaber-Fiebert,et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. , 2007, Vaccine.
[25] S. Franceschi,et al. Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update , 2007, International journal of cancer.
[26] Karen M Kuntz,et al. Multiparameter calibration of a natural history model of cervical cancer. , 2007, American journal of epidemiology.
[27] Diane Solomon,et al. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. , 2007, American journal of clinical pathology.
[28] J Dillner,et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland , 2007, British Journal of Cancer.
[29] Haesook T. Kim. Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis , 2007, Clinical Cancer Research.
[30] Erik J. Dasbach,et al. Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.
[31] Jeremy D Goldhaber-Fiebert,et al. Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. , 2006, Vaccine.
[32] M. Lehtinen,et al. Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses , 2006, PLoS medicine.
[33] Sue J Goldie,et al. Cost-effectiveness of cervical-cancer screening in five developing countries. , 2005, The New England journal of medicine.
[34] A. Muñoz,et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. , 2004, The Journal of infectious diseases.
[35] G. Sanders,et al. Evaluating Human Papillomavirus Vaccination Programs , 2004, Emerging infectious diseases.
[36] J. T. Cox,et al. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. , 2003, American journal of obstetrics and gynecology.
[37] James P. Hughes,et al. The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine , 2002, Epidemiology.
[38] S. Franceschi,et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology , 2002, British Journal of Cancer.
[39] T. Wright,et al. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. , 2002, JAMA.
[40] H. Anton-Culver,et al. A Randomized, Double Blind, Phase III Trial Using Oral β-Carotene Supplementation for Women with High-Grade Cervical Intraepithelial Neoplasia , 2001 .
[41] H. Anton-Culver,et al. A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[42] D C McCrory,et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. , 2000, American journal of epidemiology.
[43] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[44] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[45] V. Hasselblad,et al. Evaluation of cervical cytology. , 1999, Evidence report/technology assessment.
[46] Jacques Ferlay,et al. Cancer incidence in five continents. , 1976, IARC scientific publications.